A Randomized Pilot Study on the Effects of Combined Tocotrienol-Tocopherol Mixed Fraction and Vitamin C on Inflammatory Status and Lipid Profile in Statin-Treated High Risk Patients

Authors

  • Abdul Rahman TH National Defence University of Malaysia
  • Azlina AR Universiti Teknologi MARA
  • Muid S Universiti Teknologi MARA
  • Ramli AS Universiti Teknologi MARA
  • Vasudevan SK Universiti Teknologi MARA
  • Muhamed T Osman Universiti Teknologi MARA
  • Nawawi H

DOI:

https://doi.org/10.3823/1950

Keywords:

Tocotrienols, vitamin C, atherosclerosis, inflammation, endothelial activation, hypercholesterolaemia, high coronary risk.

Abstract

Previous studies have suggested that combination of Tocotrienol-tocopherol mixed fraction (TTMF) vitamin E and vitamin C supplementation act synergistically in vivo to enhance their anti-oxidant properties.  However, additional effects beyond that of anti-oxidation of combined vitamin E and vitamin C in statin-treated high coronary risk patients remains unclear. The aim of this study was to investigate pleiotropic effects of TTMF and vitamin C on inflammatory biomarkers and lipid profile in statin-treated high coronary risk patients. 

This was a pilot, randomized, double-blind, placebo controlled clinical trial. Twenty nine high coronary risk hypercholesterolaemic subjects were randomized into TTMF+C (160mg TTMF, 75% tocotrienol: 25% alpha-tocopherol plus 500mg vitamin C) intervention or placebo groups for 12 months.  Blood samples were collected at entry, baseline, 2 weeks, 3, 6 and 12 months post-randomization for analysis of inflammatory biomarkers [(high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), tumour necrosis factor alpha (TNFα)] and serum lipid profile [Total cholesterol (TC), low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c) and triglycerides (TG)]. There was no significant difference observed between TTMF+C and placebo groups with regards to percent change of hsCRP, IL-6 and TNF-α concentrations (p>0.05) and TC, LDL-c, TG and HDL-c (p>0.05) at baseline, 2 weeks, 3, 6 and 12 months of intervention. There was also no significant change seen in the mean concentration of all inflammatory biomarkers and serum lipid profile between TTMF+C and placebo groups at all timelines. TTMF and vitamin C supplementation did not significantly improve the inflammatory status and lipid profile. This could in part be contributed to the masking effect of statin’s pleiotropic properties and the possibility of alpha tocopherol in the TTMF mixture attenuating the beneficial effects of pure tocotrienols.

Author Biographies

Abdul Rahman TH, National Defence University of Malaysia

Department of Pathology, Faculty of Medicine and Defence Health

Muid S, Universiti Teknologi MARA

Department of Pathology, Faculty of Medicine.

Muhamed T Osman, Universiti Teknologi MARA

Institute of Pathology, Forensic and Laboratory Medicine (I-PPerForM)

References

Libby, P. What Have We Learned About the Biology of Atherosclerosis? The Role of Inflammation. Am. J. Cardiol 2001; 88(suppl): 3J–6J.

Berliner, J., Navab, M., Fogelman, A. M., Frank, J. S., Demer, L. L., Edwards, P. A., et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995; 91: 2488–2496.

Serbinova, E., Kagan, V., Han, D., & Packer, L. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radical Biol. Med 1991;10(5): 263–275.

Sen, C. K., Khanna, S., & Roy, S. Tocotrienols: Vitamin E beyond tocopherols. Life Sciences 2006; 78: 2088–2098.

Sen, C. K., Khanna, S., & Roy, S. Tocotrienols in health and disease: The other half of the natural vitamin E family. Mol. Aspects Med 2007; 28: 692–728.

Frei, B. Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. Am. J. Clin. Nutr 1991; 54: 113S–118S.

Suarna, C., Hood, R. L., Dean, R. T., & Stocker, R. Comparative antioxidant activitiy of tocotrienols and other natural lipid-soluble antioxidants in a homogenous system, and in rat and human lipoproteins. Biochim. Biophys. Acta 1993; 1166: 163-170.

Kamal-Eldin, A., & Appelqvist, L. A. The chemistry and antioxidant properties of tocopherols and tocotrienols. Lipids 1996;31: 671–701.

Packer JE, Slater TF, Wilson RL. Direct observationo f a free radical interaction between vitamin E and vitamin C. Nature 1979; 278: 737-38.

Yoshida Y, Niki E, Noguchi N. Comparative study on the action of tocopherols and tocotrienols as antioxidant: chemical and physical effects. CPLip 2003;123: 63-75.

Young, I. S., & Woodside, J. V. Antioxidants in health and disease. J. Clin. Pathol 2001; 54: 176-186.

Kagan, V. E., Serbinova, E. A., Forte, T., Scita, G. & Packer, L. Recycling of vitamin E in human low density lipoproteins. J. Lipid Res 1992; 33: 385–397.

Malaysian Guideline for Good Clinical Practice, Third Edition. Ministry of Health Malaysia, 2011.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc 2001; 285: 2486–2496.

"Risk Scoring Systems". http://www.framinghamheartstudy.org

WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157–63.

World Health Organisation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Genea“ WHO; 2006. ISBN 9241594934.

World Health Organisation. Physical Status. The use and interpretation of anthropometry. Geneva: WHO; 1995.

Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.

Chin, S. F., Hamid, N. A., Latiff, A. A., Zakaria, Z., Mazlan, M., Yusof, Y. A., et al. Reduction of DNA damage in older healthy adults by Tri E Tocotrienol supplementation. Nutrition 2008; 24(1): 1–10.

Roza, J. M., Xian-Liu, Z., & Guthrie, N. Effects of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolaemic subjects. Altern. Ther. Health Med 2007; 13(6): 44–48.

Salonen JT, Nyyssonen K, Salonen R et al. Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomised trial of the effect of vitamins E and C on 3-years progression of carotid atherosclerosis. J Intern Med 2000; 248: 377-86.

Plantinga, Y., Ghiadoni, L., Magagna, A., Giannarelli, C., Franzoni, F., Taddei, S. et al. Supplementation With Vitamins C and E Improves Arterial Stiffness and Endothelial Function in Essential Hypertensive Patients. A. J. H 2007; 20: 392–397.

Engler, M. M., Engler, M. B., Malloy, M. J., Chiu, E. Y., Schloetter, M. C., Paul, S. M., et al. Antioxidant Vitamins C and E Improve Endothelial Function in Children With Hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation 2003; 108: 1059–1063.

Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long term effects of pravastatin on plasma concentration of C-reactive protein Circulation 1999; 100:230-5.

Albert MA, Davidson E, Rifau N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels, the pravastatin inflammation/ CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286:64-70.

Rikitake Y, Kawashima, Takeshita S et al. Anti-oxidative properties of fluvasttin, an HMG-CoA reductase inhibitor, contribut to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154:87-96.

Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am Coll Cardiol 1998; 31:684-91.

Rasool, A. H., Yuen, K. H., Yusoff, K., Wong, A. R., & Rahman, A. R. Dose dependent elevation of plasma tocotrienol levels and its effect on arterial compliance, plasma total antioxidant status, and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E. J. Nutr. Sci. Vitaminol 2006; 52(6): 473-478.

Huang, H. Y., Helzlsouer, K. J., & Appel, L. J.. The effects of vitamin C and vitamin E on oxidative DNA damage: results from a randomized controlled trial. Cancer Epidemiol. Biomarkers Prev 2000; 9(7): 647-652.

Tardiff JC, Cote G, Lesperance J et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997; 337: 365-72.

Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomized trials. Lancet 2003; 361: 2017-2023.

Muhamed T Osman, Rahman T, Ismail TS, Azlina A.R, H. Nawawi. Investigation of oxidative stress status in metabolic syndrome patients using lipid peroxidation biomarkers. International Archives of Medicine 2016; 9(8): 1-9.

Mensink RP, AC van Houwelingen et al. A vitamin E concentrate rich in tocotrienls had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am J Cln Nutr 1999; 69(2):213-19.

Tomeo AC, Geller M et al. Antioxidant effects of tocotrienols in patients with hyperlipidaemia and carotid stenosis. Lipids 1995; 30(12): 1179-83.

Wahlqvist M, Krivokuca-Bogetic Z et al. Differential serum responses to tocopherols and tocotrienols during vitamin E supplementation in hypercholesterolaemic individuals without change in coronary risk factors. Nutr Res 1992; 12: S181-S201.

Muid S, Froemming GRA, Nawawi H. Inhibitory effects of pure tocotrienol isomers on inflammation, endothelial activation and monocyte binding activity. Atherosclerosis. 2011; 10(2): S580.

Downloads

Published

2016-05-21

Issue

Section

Laboratory Medicine